The Human Microbiota and Prostate Cancer: Friend or Foe?

被引:38
|
作者
Massari, Francesco [1 ]
Mollica, Veronica [1 ]
Di Nunno, Vincenzo [1 ]
Gatto, Lidia [1 ]
Santoni, Matteo [2 ]
Scarpelli, Marina [3 ]
Cimadamore, Alessia [3 ]
Lopez-Beltran, Antonio [4 ]
Cheng, Liang [5 ]
Battelli, Nicola [2 ]
Montironi, Rodolfo [3 ]
Brandi, Giovanni [6 ]
机构
[1] St Orsola Marcello Malpighi Hosp, Div Oncol, I-40138 Bologna, Italy
[2] Macerata Hosp, I-62100 Macerata, Italy
[3] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60126 Ancona, Italy
[4] Cordoba Univ, Dept Surg, Med Sch, Cordoba 14004, Spain
[5] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[6] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Oncol Unit, I-40138 Bologna, Italy
关键词
microbiota; microbiome; prostate cancer; genitourinary cancers; PROLIFERATIVE INFLAMMATORY ATROPHY; INTESTINAL MICROFLORA; HEALTH; PROGRESSION; DIVERSITY; APOPTOSIS; TOXICITY; EFFICACY; PROTEIN; GENE;
D O I
10.3390/cancers11040459
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human microbiome is gaining increasing attention in the medical community, as knowledge on its role not only in health but also in disease development and response to therapies is expanding. Furthermore, the connection between the microbiota and cancer, especially the link between the gut microbiota and gastrointestinal tumors, is becoming clearer. The interaction between the microbiota and the response to chemotherapies and, more recently, to immunotherapy has been widely studied, and a connection between a peculiar type of microbiota and a better response to these therapies and a different incidence in toxicities has been hypothesized. As knowledge on the gut microbiota increases, interest in the residing microbial population in other systems of our body is also increasing. Consequently, the urinary microbiota is under evaluation for its possible implications in genitourinary diseases, including cancer. Prostate cancer is the most common cancer in the male population; thus, research regarding its etiology and possible factors correlated to disease progression or the response to specific therapies is thriving. This review has the purpose to recollect the current knowledge on the relationship between the human microbiota and prostate cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Corticosteroids and Prostate Cancer: Friend or Foe?
    Geynisman, Daniel M.
    Szmulewitz, Russell Z.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY, 2015, 67 (05) : 874 - 875
  • [2] Estrogen in Prostate Cancer - Friend or Foe?
    Corey, Eva
    CURRENT CANCER THERAPY REVIEWS, 2006, 2 (04) : 341 - 349
  • [3] Glucocorticoids and prostate cancer treatment: friend or foe?
    Montgomery, Bruce
    Cheng, Heather H.
    Drechsler, James
    Mostaghel, Elahe A.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 354 - 358
  • [4] Statins for prostate cancer: a friend, a foe or neither
    Shenoy, Somanath
    Kochuparambil, Samith T.
    Al-Husein, Belal
    Goc, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 28 : S36 - S36
  • [5] PROSTATE CANCER EXTRACELLULAR VESICLES: FRIEND OR FOE
    Jankowski, Helen
    Brzozowski, Joshua
    Goldie, Belinda
    Bond, Danielle
    Munro, Benjamin
    Scarlett, Christopher
    Skelding, Kathryn
    Weidenhofer, Judith
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 10 - 10
  • [6] The role of gut microbiota in cancer treatment: friend or foe?
    Cheng, Wing Yin
    Wu, Chun-Ying
    Yu, Jun
    GUT, 2020, 69 (10) : 1867 - 1876
  • [7] The gut microbiota: friend or foe?
    Rachel David
    Nature Reviews Microbiology, 2011, 9 : 831 - 831
  • [8] The intratumoral microbiota: friend or foe?
    Ferrari, Valentina
    Rescigno, Maria
    TRENDS IN CANCER, 2023, 9 (06): : 472 - 479
  • [9] Modulating microbiota: friend or foe?
    Hohlfeld, R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 53 - 53
  • [10] Estrogen receptor beta in prostate cancer: friend or foe?
    Nelson, Adam W.
    Tilley, Wayne D.
    Neal, David E.
    Carroll, Jason S.
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : T219 - T234